1-Bromo-2-methoxyethane for Erlotinib Intermediates | High Purity
The global demand for tyrosine kinase inhibitors continues to drive rigorous standards in pharmaceutical intermediate manufacturing. Specifically, the production of Erlotinib requires precise alkylation steps to establish the critical 6,7-bis(2-methoxyethoxy) quinazoline core. Efficient organic synthesis relies heavily on the quality of the alkylating agent used to convert dihydroxy precursors into protected intermediates. As a leading global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. supplies high-grade 1-Bromo-2-methoxyethane to ensure consistent reaction kinetics and minimize side products such as N-methoxy ethyl derivatives. Selecting the correct chemical building block is essential for scaling from laboratory synthesis route optimization to commercial production without compromising yield.
Formulation compatibility and drop-in replacement advantages
- Enhanced reactivity compared to chloro-analogs reduces reaction time and corrosion risks in standard reactor vessels.
- Superior solubility profiles in polar aprotic solvents facilitate homogeneous reaction conditions during alkylation.
- Consistent industrial purity levels prevent downstream purification bottlenecks associated with halogenated impurities.
- Validated drop-in replacement capabilities for existing processes using 2-bromoethoxymethane or 2-methoxy ethyl bromide.
Technical specifications and analytical methods
| Parameter | Specification | Test Method |
|---|---|---|
| CAS Number | 6482-24-2 | N/A |
| Purity (GC) | ≥ 99.0% | Gas Chromatography |
| Water Content | ≤ 0.1% | Karl Fischer |
| Identity | Matches Reference | FTIR / 1H NMR |
| Appearance | Colorless Liquid | Visual |
Our manufacturing process ensures that every batch of 1-Bromo-2-methoxyethane meets these rigorous standards for Ethane 1-bromo-2-methoxy derivatives.
Strict Quality Assurance (QA) workflow and COA verification process
Quality control begins at raw material intake and continues through every stage of distillation and packaging. NINGBO INNO PHARMCHEM CO.,LTD. implements a multi-point inspection protocol to verify 2-methyloxyethyl bromide consistency. Each shipment is accompanied by a comprehensive COA detailing impurity profiles and physicochemical data. This transparency allows procurement teams to validate supply chain integrity and ensures R&D departments receive materials suitable for immediate use in sensitive applications.
Reliable access to high-purity intermediates is the foundation of efficient drug manufacturing. By partnering with a trusted supplier, pharmaceutical companies can mitigate production risks and maintain regulatory compliance. To request a batch-specific COA, SDS, or secure a bulk pricing quote, please contact our technical sales team.